Efficacy and safety of ixazomib in Chinese patients with multiple myeloma |
Click here to download the full text |
Citation of this paper:LI Jing△, ZHUANG Jing-li△, WEI Zheng, JI Li-li, CHENG Zhi-xiang, GAO Ru-pan, ZHANG Yi-an, CHEN Chen, ZHANG Xue-jiao, LIU Peng*.Efficacy and safety of ixazomib in Chinese patients with multiple myeloma[J].Chinese Journal of Clinical Medicine,2019,26(2):218-223 |
Hits: 3657 |
Download times: 1046 |
Author Name | Affiliation | LI Jing△, ZHUANG Jing-li△, WEI Zheng, JI Li-li, CHENG Zhi-xiang, GAO Ru-pan, ZHANG Yi-an, CHEN Chen, ZHANG Xue-jiao, LIU Peng* | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China |
|
Abstract:Objective:To evaluate the efficacy and safety of ixazomib, an oral proteasome inhibitor, in patients with multiple myeloma (MM).
Methods:MM patients (patients with light chain amyloidosis and plasma cell leukemia were excluded) received 2 cycles or more of ixazomib therapy were selected in Zhongshan Hospital, Fudan University Between July 1, 2018 and April 4, 2019. The treatment included single ixazomib agent and doublet- or triplet-drug regimens combined with other agents (lenalidomide, thalidomide, or dexamethasone, etc.). Patients received ixazomib at an initial dose of 4 mg (day 1, 8, and 15) in a 28-days cycle. Response assessment and safety were analyzed in all patients at the end of the 2nd cycle and 4th cycle.
Results:A total of 27 eligible patients including 15 refractory/relapsed MM and 12 newly diagnosed MM were enrolled. The overall response rate (ORR) in refractory/relapsed MM was 53.3%, with 2 patients had complete response (CR), 1 had very good partial response (VGPR), 5 had partial response (PR). The median time to response was 53 d in refractory/relapsed patients. The ORR was 54.5% (6/11) in bortezomib-refractory patients. The ORR in 9 evaluable previously untreated MM patients was 100.0%, with 2 had CR, 3 had VGPR, and 4 had PR. The median time to response was 38 d in newly diagnosed patients. Grade 3-4 adverse events (AE) were reported in 29.6% patients. Common hematological AEs included lymphopenia, neutropenia, thrombocytopenia, and anemia. Other common AEs were fatigue and gastro-intestinal response. No grade 3-4 peripheral neuropathy was recorded.
Conclusions:In real-world setting, ixazomib is generally effective and safe in newly diagnosed and relapsed/refractory MM patients in China. |
keywords:multiple myeloma ixazomib efficacy safety adverse events |
HTML View Full Text View/Add Comment Download reader |
|
|
|